Patents Issued in June 27, 2017
-
Patent number: 9687426Abstract: Composition containing an aqueous phase and an emulsifying system, where the emulsifying system contains at least one C10-C30 alkyl phosphate and at least one C8-C24 fatty alkyl ether of polyethylene glycol, the ether comprising from 1 to 19 ethylene glycol units and having an HLB<8 at 25° C. Process for making up or for non-therapeutically caring for keratin fibres, via the application to keratin fibres of the composition. Uses of the composition in particular for obtaining uniform and/or thick makeup on keratin fibres, and as mascara for making up keratin fibres.Type: GrantFiled: November 5, 2007Date of Patent: June 27, 2017Assignee: L'OREALInventors: Olivier Raineau, Isabelle Jacquier
-
Patent number: 9687427Abstract: Oral care composition comprises a stannous ion source and a thickener comprising at least 2 agents selected from the group consisting of: i) a linear sulfated polysaccharide; ii) a natural gum; iii) and a non-ionic cellulose derivative. A method for treating the oral cavity comprises administering to the oral cavity the oral care composition.Type: GrantFiled: February 27, 2015Date of Patent: June 27, 2017Assignee: The Procter & Gamble CompanyInventors: Xiaoxiao Li, Yujun Li, Ross Strand, Xiujun Xu
-
Patent number: 9687428Abstract: A composition is provided, wherein the composition comprises a water-swellable, water insoluble polymer, a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding to the hydrophilic polymer, and a whitening agent, preferably a peroxide. The composition finds utility as a tooth whitening composition and is applied to the teeth in need of whitening, and then removed when the degree of whitening has been achieved. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: November 23, 2016Date of Patent: June 27, 2017Assignees: A. V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCES, CORIUM INTERNATIONAL, INC.Inventors: Parminder Singh, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bayramov
-
Patent number: 9687429Abstract: The present invention relates to a preservative or antimicrobial compositions with broad spectrum antimicrobial activity comprising low concentrations of essential oil (and/or one or more component thereof) and a botanical extract in synergistic combination with a fruit acid and alkanediol, and optionally a solvent. The compositions of the invention may be used in personal care products such as creams or soap products.Type: GrantFiled: January 26, 2010Date of Patent: June 27, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Shanta Modak, Nayana Baiju, Lauserpina Caraos
-
Patent number: 9687430Abstract: One aspect of the present invention relates to an effervescent tablet comprising a water-soluble lubricating agent, and a carbonated water cosmetic composition enabled to be used together therewith. One aspect of the present invention relates to an effervescent tablet comprising a crystalline #-hydroxy acid and a water-soluble lubricating agent, and a cosmetic composition using a skin toner for preventing the tablet from floating and allowing the tablet to rapidly form carbon dioxide gas in the cosmetic composition so as to maximize the visual effect and also the effect of carbon dioxide, thereby showing skin whitening, brightening and moisturizing effects and improving the pores.Type: GrantFiled: March 21, 2014Date of Patent: June 27, 2017Assignee: AMOREPACIFIC CORPORATIONInventors: Ju A Jung, Byung Ryol Paik, Chang Keun Lee, Lee Kyoung Kwon, Joon Ho Bae, Young So Kim
-
Patent number: 9687431Abstract: The invention relates to the cosmetic use of isoleucine N-hexadecanoyl of formula (I): CH3—(CH2)14—C(?O)—NH—CH(COOH)—CH(CH3)—CH2—CH3 (I) as a “volumizing” agent and/or as a “plumping” agent for human skin. The invention also relates to a cosmetic treatment method for obtaining a “volumizing” and/or “plumping” effect of the skin of a part of the human body selected from among the breasts, face, cheeks, buttocks and eyelids.Type: GrantFiled: July 22, 2010Date of Patent: June 27, 2017Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPICInventors: Laetitia Cattuzzato, Nathalie Chevrot, Sandy Dumont, Corinne Stoltz
-
Patent number: 9687432Abstract: Antimicrobial bispyridine amine compositions that facilitate easy application on the skin, do not penetrate the skin, are compatible with typical deodorant ingredients, and do not cause adverse effects on skin and clothing. In one aspect, the present invention relates to an antimicrobial composition including an organic acid salt of a bispyridine amine where the organic acid contains from about 4 to about 30 carbon atoms. Because the organic acid salts of bispyridine amines are large molecules, they will not easily penetrate the skin, and will stay on the surface where they were applied and where they are needed to have their effect.Type: GrantFiled: December 23, 2013Date of Patent: June 27, 2017Assignee: LONZA INC.Inventors: James V. Gruber, Diana Ciccognani, Volodymyr B. Pashovych
-
Patent number: 9687433Abstract: The present invention is relates to a novel anhydrous dermatological depigmenting compositions comprising a phenolic compound, and methods of making and using the same.Type: GrantFiled: October 9, 2015Date of Patent: June 27, 2017Assignee: Ecstasy LLCInventors: Xiaodong Wang, Hua Zhong
-
Patent number: 9687434Abstract: The present invention relates to the cosmetic use by external topical route of steviol, of a steviol glycoside derivative or of one of their isomers to stimulate, restore or regulate the metabolism of the cells of the skin.Type: GrantFiled: December 21, 2012Date of Patent: June 27, 2017Assignee: L'OREALInventors: Julien Laboureau, Myrian Kauffmann, Yann Mahe
-
Patent number: 9687435Abstract: It is intended to provide a liquid oral composition and a liquid food composition in which calcium phosphate such as hydroxyapatite or tricalcium phosphate can be stably dispersed and prevented from being precipitated or separated out even in long-term storage. Calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester can be stably dispersed even in long-term storage and prevented from being precipitated or separated out even when used in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents or in liquid food compositions such as milk, soy milk, yoghurt, and refreshing beverages. In addition, calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester further supplemented with an amphoteric surfactant can be more effectively prevented from being precipitated or separated out in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents.Type: GrantFiled: January 28, 2013Date of Patent: June 27, 2017Assignee: KABUSHIKI KAISHA SANGIInventors: Keijiro Fujita, Mariko Obuki, Tomoki Saito, Shuji Sakuma
-
Patent number: 9687436Abstract: The present invention relates to a nail varnish composition which contains a plasticizer A) and a film-forming agent B), characterized in that the plasticizer A) comprises at least two carbonate structural units of formula (I) and has an average molecular weight of ?450 g/mol, determined by gel permeation chromatography against a polystyrene standard in tetrahydrofurane at 23° according to DIN 55672-1, and a hydroxyl functionality of ?1.5 and ?6. The invention further relates to a coating which can be obtained from the nail varnish composition according to the invention, to a substrate coated with such a coating, and to a cosmetic method for coating finger and/or toe nails, according to which method a nail varnish composition according to the invention is applied to finger and/or toe nails. The invention also relates to the use of compounds as plasticizers in nail varnish compositions which compounds contain specific carbonate structural units.Type: GrantFiled: September 19, 2014Date of Patent: June 27, 2017Assignee: Covestro Deutschland AGInventors: Sophie Viala, Sebastian Dorr
-
Patent number: 9687437Abstract: Compositions and methods are disclosed for preventing or reducing frizzy appearance of keratin fibers, including hair, and reducing the amount of fly-away strands of hair, particularly in humid conditions, by forming a coating on hair that is resistant to water vapors from the air or surrounding environment. The compositions comprise a combination of a hydrophobic particulate material comprising a hydrophobically surface-modified aluminum oxide and one or more hydrophobic film formers in a cosmetically acceptable vehicle.Type: GrantFiled: December 4, 2014Date of Patent: June 27, 2017Assignee: Avon Products, IncInventors: Mark S. Garrison, Freda E. Robinson, Giovana A. Sandstrom, Kenneth A. Buckridge, Sen Yang, Xiaochun Luo
-
Patent number: 9687438Abstract: Provided is a method for enhancing collagen secretion and preventing cutaneous aging using Chenopodium formosanum extract. The Chenopodium formosanum extract includes active ingredients that are able to effectively enhance the ability of collagen secretion of dermal fibroblasts as well as prevent the glycation of collagen and resist the damage of ultraviolet light exposure. The preparation of the Chenopodium formosanum extract is environmental friendly and is able to promote the economic value of Chenopodium formosanum; thus, the present invention is suitable for applications in the development of food products, especially beverages, skin care and cosmetic products.Type: GrantFiled: March 3, 2015Date of Patent: June 27, 2017Assignee: TCI Co., Ltd.Inventors: Hsiang-Ling Su, Chin-Hsiu Yu, Ying-Ju Chen
-
Patent number: 9687439Abstract: A composition comprising an extract from damaged plant parts from the Moringaceae genus, at least one oligopeptide, at least one extract from the Laminaria genus, and whey protein and a method for stimulating collagen synthesis in skin cells.Type: GrantFiled: January 21, 2016Date of Patent: June 27, 2017Assignee: ELC Management LLCInventors: Nadine Pernodet, Krystle Corallo, Dawn Layman, Donald Collins
-
Patent number: 9687440Abstract: Compositions comprising at least one ingredient that stimulates, enhances, or increases CGRP expression, and a physiologically- or cosmetically-acceptable vehicle. The ingredient may be a compound, natural ingredient, such as a plant or fungus, derivatives, analogs, mimetics, synthetics and the like that stimulates CGRP expression. The CGRP plant includes plants, plant materials, plant extracts, synthetics, or combinations thereof that stimulate CGRP expression. The disclosure is also directed to methods of using the CGRP compositions for decreasing, reducing, or inhibiting fine lines or wrinkled skin.Type: GrantFiled: March 26, 2015Date of Patent: June 27, 2017Assignee: Avon Products, IncInventors: John W. Lyga, Laurence Dryer
-
Patent number: 9687441Abstract: Compositions for lubricating skin during application of a fascia tissue treatment device, thereby reducing the appearance of cellulite in skin and methods of forming such compositions.Type: GrantFiled: June 14, 2016Date of Patent: June 27, 2017Assignee: Ashley Diana Black International Holdings, LLCInventor: Ashley D. Black
-
Patent number: 9687442Abstract: The present invention relates generally to methods and compositions useful for application to skin and hair comprising hydrolyzed algae extract, saccharide isomerate, and a dermatologically acceptable vehicle wherein the composition or method is capable of moisturizing and/or improving the appearance and/or condition of skin and/or hair.Type: GrantFiled: July 25, 2016Date of Patent: June 27, 2017Assignee: Mary Kay Inc.Inventors: Tiffany Carle, Bob Foley, Julia Collier, Wanli Zhao, Geetha Kalahasti
-
Patent number: 9687443Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Type: GrantFiled: February 19, 2016Date of Patent: June 27, 2017Assignee: ALLERGAN, INC.Inventors: Richard Graham, Peter Bakhit, Orest Olejnik
-
Patent number: 9687444Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.Type: GrantFiled: March 28, 2014Date of Patent: June 27, 2017Inventor: Andrew L. Skigen
-
Patent number: 9687445Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.Type: GrantFiled: April 12, 2012Date of Patent: June 27, 2017Assignee: LTS Lohmann Therapie-Systeme AGInventor: Michael Hsin Chwen Li
-
Patent number: 9687446Abstract: The present invention is drawn to methods of preparing a bioactive agent-containing emulsion for delivery to a biological system. This method can comprise the step of jetting a bioactive agent and a first fluid medium from a fluid-jet pen into a second fluid medium to form a bioactive agent-containing emulsion, wherein the second fluid comprises a continuous phase of the emulsion. Alternatively, a method of preparing a bioactive agent-containing liposome can comprise jetting a lipid-containing composition and a bioactive agent from a fluid-jet pen into a medium to form a bioactive agent-containing liposome carried by the medium. The present invention is also drawn to fluid-jet pens and systems configured for making liposome- and emulsion-containing biological agents.Type: GrantFiled: August 31, 2009Date of Patent: June 27, 2017Assignee: Hewlett-Packard Development Company, L.P.Inventors: John Stephen Dunfield, James W. Ayres
-
Patent number: 9687447Abstract: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.Type: GrantFiled: October 26, 2011Date of Patent: June 27, 2017Assignee: AC Immune S.A.Inventors: Pedro Reis, David Hickman, Maria Pihlgren Bosch, Andreas Muhs, Andrea Pfeifer
-
Patent number: 9687448Abstract: The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.Type: GrantFiled: December 4, 2013Date of Patent: June 27, 2017Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Akin Akinc, Martin Maier, Varun Kumar
-
Patent number: 9687449Abstract: A delivery vehicle for bioactive agents and live probiotic microbes to aquatic animals protects the bioactive compounds and microbes from digestion and destruction in the animal stomach. It provides for controlled release of bioactive agents and live probiotic microbes to aquatic animals in the form of dry or wet beadlets with essential nutrients and attractants bound with soluble starch and cross-linked alginate. The bioactive agents and live probiotic microbes can be bound with emulsified high-amylose starch and embedded in the beadlets in the form of microparticles.Type: GrantFiled: November 6, 2003Date of Patent: June 27, 2017Assignee: Advanced Bionutrition Corp.Inventor: Moti Harel
-
Patent number: 9687450Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.Type: GrantFiled: February 26, 2016Date of Patent: June 27, 2017Assignee: Covidien LPInventors: Phillip Blaskovich, Valentino Tramontano, Joshua Kennedy, Rachit Ohri
-
Patent number: 9687451Abstract: A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer.Type: GrantFiled: March 22, 2010Date of Patent: June 27, 2017Assignee: GLATT AIR TECHNIQUES, INC.Inventors: Orapin P. Rubino, David M. Jones
-
Patent number: 9687452Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: GrantFiled: April 22, 2015Date of Patent: June 27, 2017Assignee: Curemark, LLCInventors: Joan M. Fallon, Matthew Heil
-
Patent number: 9687453Abstract: [Problem] To provide a novel pharmaceutical composition which contains a medically active component and which can suppress delays in the release of said component due to gelling. [Solution] This solid pharmaceutical composition contains a compound represented by general formula (1), or a salt thereof, a cellulosic excipient, and a salting-out agent.Type: GrantFiled: April 24, 2014Date of Patent: June 27, 2017Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Uchida, Masataka Hanada, Yoshikazu Miyazaki
-
Patent number: 9687454Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: GrantFiled: January 6, 2016Date of Patent: June 27, 2017Assignee: Indivior UK LimitedInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Patent number: 9687455Abstract: Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier.Type: GrantFiled: August 14, 2015Date of Patent: June 27, 2017Inventor: John Daniel Dobak
-
Patent number: 9687456Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, a nutritional composition includes exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.Type: GrantFiled: April 14, 2016Date of Patent: June 27, 2017Assignee: Nestec S.A.Inventors: Douglas Richard Bolster, Zamzam Kabiry Roughead
-
Patent number: 9687457Abstract: Problem to be Solved by the Invention: To providing a method for ameliorating DHIC. Means for Solving the Problem: This invention is directed to a treating method for DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.Type: GrantFiled: May 16, 2016Date of Patent: June 27, 2017Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Yukio Hayashi, Takahisa Noma
-
Patent number: 9687458Abstract: The present invention relates to the administration of compositions comprising an antiestrogen, preferably a selective estrogen receptor modulator (SERM) such as trans-clomiphene, for treating cancer and associated diseases. The invention is also directed to methods for reducing IGF-1 levels in a subject in need thereof by administering a composition comprising an antiestrogen, preferably a SERM such as trans-clomiphene.Type: GrantFiled: October 22, 2013Date of Patent: June 27, 2017Assignee: Repros Therapeutics Inc.Inventors: Joseph S. Podolski, Ronald D. Wiehle, Kuang Hsu, Greg Fontenot
-
Patent number: 9687459Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.Type: GrantFiled: September 12, 2016Date of Patent: June 27, 2017Assignee: PIERRE FABRE MEDICAMENTInventors: Bernard Vacher, Elodie Blanc, Ronan Depoortere
-
Patent number: 9687460Abstract: This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.Type: GrantFiled: May 26, 2014Date of Patent: June 27, 2017Assignee: SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIMInventor: Uriel Heresco-Levy
-
Patent number: 9687461Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.Type: GrantFiled: December 28, 2015Date of Patent: June 27, 2017Assignee: The United States of America, as Represented by the Secretary of the NavyInventor: Stephanie Venn-Watson
-
Patent number: 9687462Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.Type: GrantFiled: November 10, 2016Date of Patent: June 27, 2017Assignees: Nestec S.A., Beth Israel Deaconess Medical Center, Inc.Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
-
Patent number: 9687463Abstract: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.Type: GrantFiled: September 29, 2015Date of Patent: June 27, 2017Assignee: The William M. Yarbrough FoundationInventor: Michael E. Silver
-
Patent number: 9687464Abstract: There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided.Type: GrantFiled: March 11, 2011Date of Patent: June 27, 2017Assignee: Agency for Science, Technology and ResearchInventors: Motoichi Kurisawa, Kun Liang, Susi Tan, Joo Eun Chung, Jackie Y. Ying
-
Patent number: 9687465Abstract: The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from.Type: GrantFiled: November 27, 2012Date of Patent: June 27, 2017Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Hanan Sertchook, Ofer Toledano, Haim Bar-Simantov
-
Patent number: 9687466Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.Type: GrantFiled: April 4, 2014Date of Patent: June 27, 2017Assignee: DELMAR PHARMACEUTICALS, INC.Inventors: Jeffrey A. Bacha, Dennis Brown, Sandra Dunn, Anne Steinø
-
Patent number: 9687467Abstract: Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof.Type: GrantFiled: April 4, 2012Date of Patent: June 27, 2017Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Amy Holleman, Ivy Chung
-
Patent number: 9687468Abstract: The present invention relates to the preparation of Cynara scolymus leaf extracts, which are useful for the prevention and treatment of dyslipidaemia, in particular to increase HDL cholesterol in patients at cardiovascular risk. Said extracts are useful to normalize the lipid and carbohydrate balances and significantly increase the value of HDL cholesterol by favorably changing the LDL/HDL ratio, especially in post-infarction patients with drug-induced dyslipidaemia.Type: GrantFiled: September 13, 2012Date of Patent: June 27, 2017Assignee: INDENA S.P.A.Inventor: Ezio Bombardelli
-
Patent number: 9687469Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.Type: GrantFiled: August 25, 2015Date of Patent: June 27, 2017Assignees: University of Maryland, Baltimore, Educational & Scientific LLCInventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
-
Patent number: 9687470Abstract: A method for the prevention of filariasis includes administering to a subject a therapeutically effective amount of a compound of the general formula (1) or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (1), wherein, R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b):Type: GrantFiled: March 16, 2015Date of Patent: June 27, 2017Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAET BONNInventors: Kenneth Michael Pfarr, Achim Hoerauf, Gabriele Maria Koenig, Sabine Specht, Andrea Schiefer, Till Friedrich Schaeberle, Alexander Schmitz, Stefan Kehraus
-
Patent number: 9687471Abstract: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves sequential additions of ascorbic acid and ethoxydiglycol to a first solution of vitamin in water, which are followed by addition of propylene glycol. The stirring speed that occurs during the additions favors a process of micronization. Mild heating is used to achieve ascorbic acid concentrations equivalent to about 6% in 10% water or higher.Type: GrantFiled: January 29, 2014Date of Patent: June 27, 2017Assignee: VIVIER CANADA INC.Inventors: Ghislain Vivier, Anthony Costa
-
Patent number: 9687472Abstract: The current application teaches methods and compositions useful for the treatment of cancer through administration of an antioxidant together with an immune stimulator at concentrations sufficient to augment antitumor immunity while simultaneously preventing inhibition of T cell function as a result of tumor secreted oxidative stress. Compositions such as toll like receptor agonists in combination with antioxidants are disclosed. In further embodiments, the application teaches the use of antioxidants to prevent immunotherapy associated oxidative stress, of which, one manifestation is vascular leak syndrome. In one specific embodiment, the application teaches the use of intravenous ascorbic acid as a means of reducing IL-2 associated toxicity.Type: GrantFiled: May 7, 2015Date of Patent: June 27, 2017Assignee: Batu BiologicsInventors: Samuel C. Wagner, Andy J. Kim, Dimitri N. Theofilopoulos, Brandon R. Dolan, Naseem Ajili
-
Patent number: 9687473Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.Type: GrantFiled: March 30, 2016Date of Patent: June 27, 2017Assignee: H. LUNDBECK A/SInventors: Ellen Schmidt, Johan Areberg
-
Patent number: 9687474Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.Type: GrantFiled: July 25, 2013Date of Patent: June 27, 2017Assignee: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Masayuki Suzuki, Hiroaki Okutsu, Takashi Yasukochi, Yasunori Takada
-
Patent number: 9687475Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.Type: GrantFiled: March 24, 2016Date of Patent: June 27, 2017Assignees: Ezra Pharma LLC, Rubicon Research Private LimitedInventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi